在多参数MRI时代,Grade Group 1前列腺癌主动监测是否仍需确认性活检
本研究纳入诊断活检为Grade Group 1前列腺癌并考虑主动监测的男性,评估确认性活检(系统+靶向)的 grade 再分类率。阳性MRI者再分类率较高,阴性MRI者所有再分类结局均<10%,数据支持阳性MRI者行系统+靶向确认性活检,阴性MRI者可推迟确认性活检。
要点
- 确认性活检时20%再分类至GG≥2,12%至不利中间风险,5.6%至GG≥3。
- 阳性MRI者27%再分类至GG≥2、16%至不利中间风险;阴性MRI者分别为9.2%和5.5%。
- MRI时机不影响再分类结局,PSA密度和前列腺体积未增加MRI信息。
核心结论
- 阳性MRI男性确认性活检再分类率高,但阴性MRI男性所有再分类结局均<10%(GG≥2的95%CI为5.8%-14%;不利中间风险的95%CI为2.9%-10%;GG≥3的95%CI为0.8%-5.3%)。
- 数据支持对考虑主动监测的阳性MRI男性行系统+靶向确认性活检,而GG1且阴性MRI男性应能够推迟确认性活检。
研究设计与样本
- 研究纳入诊断活检为Grade Group 1前列腺癌、考虑主动监测、并在18个月内接受MRI和确认性活检(系统+靶向)的男性。
- 共522名男性在诊断活检时为GG1前列腺癌。
- 对诊断活检前接受MRI和诊断活检后接受MRI的男性进行亚组分析。
主要发现
- 确认性活检时,20%再分类至GG≥2,12%再分类至不利中间风险疾病,5.6%再分类至GG≥3。
- 306名阳性MRI(前列腺影像报告和数据系统≥3)男性中,27%再分类至GG≥2,16%再分类至不利中间风险疾病;阴性MRI男性这些结局的发生率分别为9.2%和5.5%。
- 基于MRI时机(A组 vs B组)的再分类结局无差异,PSA密度和前列腺体积均未增加MRI信息。
- 在具有MRI靶点的男性中,约三分之一的GG≥2再分类事件仅由系统活检核心捕获。
临床怎么用
- 作者认为,数据支持对考虑主动监测的阳性MRI男性行系统+靶向确认性活检。
- 作者认为,GG1且阴性MRI男性应能够推迟确认性活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Men diagnosed with prostate cancer (PCa) considering active surveillance (AS) are recommended confirmatory biopsy (CBx). Whether this is necessary in the era of MRI-informed biopsies is questionable. MATERIALS AND METHODS: We studied men with Grade Group (GG) 1 PCa at diagnostic biopsy (DBx) considering AS who underwent MRI and CBx (systematic + targeted) within 18 months. Outcomes were grade reclassification to GG ≥ 2 and GG ≥ 3 and reclassification to unfavorable intermediate-risk (UIR) disease. Subset analyses were performed for men with (1) MRI before DBx and (2) MRI after DBx. RESULTS: Five hundred twenty-two men had GG1 PCa at DBx. At CBx, 20% reclassified to GG ≥ 2, 12% to UIR disease, and 5.6% to GG ≥ 3. Of the 306 with positive MRI (Prostate Imaging Reporting and Data System ≥3), 27% reclassified to GG ≥ 2 and 16% to UIR disease; men with negative MRI experienced these outcomes at rates of 9.2% and 5.5%, respectively. There were no differences in reclassification outcomes based on MRI timing (group A vs B), and neither PSA density nor prostate volume added to MRI information. In men with MRI targets, approximately one-third of GG ≥ 2 reclassification events were only captured by systematic biopsy core(s). CONCLUSIONS: Reclassification rates at CBx were high in men with positive MRI, but < 10% for all reclassification outcomes in men with negative MRI (95% CI, 5.8%-14% for GG ≥2; 95% CI, 2.9%-10% for UIR; 95% CI, 0.8%-5.3% for GG ≥3). Our data support systematic + targeted CBx for men with positive MRI considering AS, whereas men with GG1 cancer and negative MRI should be able to defer CBx.
引用
- Bhanji Y, Mamawala MK, Fletcher SA, et al. Is Confirmatory Biopsy Still Necessary for Active Surveillance of Men With Grade Group 1 Prostate Cancer in the Era of Multiparametric MRI? J Urol. 2024. PMID: 39357025. doi:10.1097/JU.0000000000004268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。